Wednesday, June 10, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 43 of 1,261
  1. US 12297452

    Methods or generating T-cells from stem cells and immunotherapeutic methods using the T-cells

    The Regents of the University of California Β· Granted May 13, 2025 Β· Expires May 8, 2045

    granted
  2. US 12295929

    Intravenous baclofen formulations and treatment methods

    Regents of the University of Minnesota Β· Granted May 13, 2025 Β· Expires May 8, 2045

    granted
  3. US 12296004

    Recombinant virus with diminished latency and methods of using same

    The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted May 13, 2025 Β· Expires May 8, 2045

    granted
  4. US 12296025

    AAV capsid variants and uses thereof

    VOYAGER THERAPEUTICS, INC. Β· Granted May 13, 2025 Β· Expires May 8, 2045

    granted
  5. US 12295940

    Viral inhibitors, the synthesis thereof, and intermediates thereto

    Takeda Pharmaceutical Company Limited Β· Granted May 13, 2025 Β· Expires May 8, 2045

    granted
  6. US 12296050

    Pharmaceutical compositions comprising maralixibat and uses thereof

    MIRUM PHARMACEUTICALS, INC. Β· Granted May 13, 2025 Β· Expires May 8, 2045

    granted
  7. US 12298315

    Systems and methods to identify and treat subjects at risk for obstetrical complications

    The United States of America as Represented by the Secretary, Dept. of Health and Human Services Β· Granted May 13, 2025 Β· Expires May 8, 2045

    granted
  8. US 12295362

    Formulations and processes for CAR T cell drug products

    Allogene Therapeutics, Inc. Β· Granted May 13, 2025 Β· Expires May 8, 2045

    granted
  9. US 12297431

    Modulation of huntingtin expression

    Ionis Pharmaceuticals, Inc. Β· Granted May 13, 2025 Β· Expires May 8, 2045

    granted
  10. US 12296047

    Manufacturing of bupivacaine multivesicular liposomes

    Pacira Pharmaceuticals, Inc. Β· Granted May 13, 2025 Β· Expires May 8, 2045

    granted
  11. US 12297207

    Maytansinoid derivatives, conjugates thereof, and methods of use

    REGENERON PHARMACEUTICALS, INC. Β· Granted May 13, 2025 Β· Expires May 8, 2045

    granted
  12. US 12295971

    Compositions and methods for enhancing adoptive T cell therapeutics

    The Regents of the University of California Β· Granted May 13, 2025 Β· Expires May 8, 2045

    granted
  13. US 12296023

    Chemically and photochemically initiated cell membrane blebbing to induce cell vesicle production, modifications thereof, and uses thereof

    The Regents of the University of California Β· Granted May 13, 2025 Β· Expires May 8, 2045

    granted
  14. US 12297447

    Gene therapy for juvenile Batten disease

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA Β· Granted May 13, 2025 Β· Expires May 8, 2045

    granted
  15. US 12297209

    Benzodiazepine derivatives as RSV inhibitors

    Enanta Pharmaceuticals, Inc. Β· Granted May 13, 2025 Β· Expires May 8, 2045

    granted
  16. US 12295941

    Viral inhibitors, the synthesis thereof, and intermediates thereto

    Takeda Pharmaceutical Company Limited Β· Granted May 13, 2025 Β· Expires May 8, 2045

    granted
  17. US 12297186

    Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor I/ALK5

    AGOMAB SPAIN, S.L.U. Β· Granted May 13, 2025 Β· Expires May 8, 2045

    granted
  18. US 12295909

    Adapter for use in a planetary mixer

    MEDISCA PHARMACEUTIQUE INC. Β· Granted May 13, 2025 Β· Expires May 8, 2045

    granted
  19. US 12297202

    RIP1K inhibitors

    Rigel Pharmaceuticals, Inc. Β· Granted May 13, 2025 Β· Expires May 8, 2045

    granted
  20. US 12295394

    Water-soluble additive composition

    SUMITOMO BAKELITE CO., LTD. Β· Granted May 13, 2025 Β· Expires May 8, 2045

    granted
  21. US 12297241

    Method to engineer transplantable human tissues

    The Regents of the University of California Β· Granted May 13, 2025 Β· Expires May 8, 2045

    granted
  22. WO 2025096967

    REDIRECTION DE CAPSIDES D'AAV POUR CIBLAGE DU SYSTÈME NERVEUX CENTRAL

    BIOGEN MA INC [US] Β· Granted May 8, 2025 Β· Expires May 3, 2045

    granted
  23. US 12290566

    Dosing regimens and related compositions and methods

    Apellis Pharmaceuticals, Inc. Β· Granted May 6, 2025 Β· Expires May 1, 2045

    granted
  24. US 12290596

    Compositions and methods for the treatment of opioid overdose

    Indivior UK Limited Β· Granted May 6, 2025 Β· Expires May 1, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.